NICE, the UK HMO, Publishes Guidance on Dietary Interventions and physical activity interventions for weight management before, during and after pregnancy

Full Text Here

The Department of Health (DH) asked the National Institute for Health and Clinical Excellence (NICE) to produce public health guidance on dietary and physical activity interventions for weight management before, during and after pregnancy.
The guidance does not cover:
• women who are underweight (that is, those who have a body mass index [BMI] less than 18.5 kg/m²)
• clinical management of women who are obese during pregnancy
• those who have been diagnosed with, or who are receiving treatment for, an existing condition such as type 1 or type 2 diabetes
• food safety advice.
The guidance is for NHS and other commissioners, managers and professionals who have a direct or indirect role in, and responsibility for, women who are pregnant or who are planning a pregnancy and mothers who have had a baby in the last 2 years. This includes those working in local authorities, education and the wider public, private, voluntary and community sectors.
It is particularly aimed at: GPs, obstetricians, midwives, health visitors, dietitians, community pharmacists and all those working in antenatal and postnatal services and children’s centres. It may also be of interest to women before, during and after pregnancy and their partners and families, and other members of the public.
The guidance complements but does not replace NICE guidance on: obesity, maternal and child nutrition, antenatal care, postnatal care, physical activity, behaviour change, antenatal and postnatal mental health and diabetes in pregnancy (for further details, see section 7).

NICE public health guidance 27: Weight management before, during and after
pregnancy
4 of 60
The Public Health Interventions Advisory Committee (PHIAC) developed these recommendations on the basis of a review of the evidence, economic modelling, expert advice, stakeholder comments and fieldwork.
Members of PHIAC are listed in appendix A. The methods used to develop the guidance are summarised in appendix B.
Supporting documents used to prepare this document are listed in appendix E. Full details of the evidence collated, including fieldwork data and activities and stakeholder comments, are available on the NICE website, along with a list of the stakeholders involved and NICE’s supporting process and methods manuals. The website address is: www.nice.org.uk

For a Market Access and Health Economics Expert Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”